Jen Norton appointed market access leader at EVERSANA
EVERSANA has named Jen Norton as president of its Market Access & Value division, which helps life sciences companies secure optimal pricing, ensure broad payer coverage, and drive patient access for therapies.
Norton has been brought on board at EVERSANA – pharmaphorum's parent company – to lead the development of a "technology-first, fully integrated market access business unit."
The aim is to assist clients in navigating what is becoming an increasingly complex pricing and access landscape around the world, marked by initiatives such as the Medicare price negotiations and most-favoured nation policies in the US, regulatory reforms and health technology assessment overhauls in Europe, and the impact of tariffs on international trade.
Norton is bringing more than two decades of experience to her new role at EVERSANA, most recently at Takeda Pharmaceuticals, where she spent three years as senior vice president of US Patient and Market Access (PAMA).
She has previously held leadership market access roles at Amgen, Biogen, and Vertex Pharma, and spent several years in consultancy roles at companies specialising in contract lifecycle management, compliance, and complex pricing/rebate systems, whilst also serving on the board of directors of the National Pharmaceutical Council.
That experience has built "a deep understanding of the evolving payer, provider, and patient environment," according to EVERSANA.
The company said the formation of a dedicated market access group reinforces its commitment to the sector and brings its expertise in global pricing, revenue management, value and evidence, and consulting offerings under one unit.
"Successfully navigating market access is one of the most critical challenges our clients face today. Investing in a dedicated, unified market access team under a proven leader is a testament to our commitment to their success," said Mark Thierer, EVERSANA's chief executive.
"Jen's deep experience and track record of building and leading high-performing access teams at top pharmaceutical companies make her the perfect leader to spearhead this crucial initiative," he added. "We are thrilled to have her join our team to deliver unparalleled value for our clients."
